The 2026 Medtech Regulatory Surge Makes Technology Architecture a Board-Level Decision

Historically, medtech companies have defined enterprise architecture as a series of separate technology choices, such as PLM, CRM, and quality systems to support foundational processes for specific departmental needs. However, a surge of change in the global regulatory landscape is challenging this model. 

This year, implementation deadlines and enforcement mandates are approaching for the Medical Device Regulation (MDR), In Vitro Diagnostic Regulation (IVDR), and the EU AI Act, prompting the European Commission to propose revisions to work out how the bodies of legislation converge. Simultaneously, four core modules of EUDAMED will become mandatory in May 2026, and the Corporate Sustainability Reporting Directive (CSRD) will add new requirements for auditable systems and verified data. And earlier this year, the U.S. FDA implemented the Quality Management System Regulation (QMSR) to align with international standards.

In this dynamic regulatory environment, enterprise design is a strategic decision for executive teams. Beyond just an IT concern, enterprise architecture now defines how companies navigate changing regulations and build towards future innovation.

From Platform Selection to Connected Enterprise Design

As medtech companies modernize, selecting high-capability platforms is still critical. But the challenge is often not a lack of technology­—it is the compounded strain of disconnected or heavily customized systems that cannot keep up with today’s pace of change. The true value of those systems comes from how they work together within the wider enterprise.

Architecture should reflect the organizational, legal, and geographical structure of the business. Considering how and where a business brings products to market informs capability needs and data standards from the outset. When integrated into system design, consistent governance and standardized processes help maintain alignment across business units, third-party distributors, and other external partners. When these factors are disconnected from technology choices, complexity can build over time.

New regulations such as MDR and IVDR, the EU AI Act, and CSRD demand higher standards for traceability and reporting, and platforms that are cohesive across functions and adaptable to regulatory evolution allow companies to respond faster. A well-designed system architecture that is easily upgradeable and considers medtech’s specific needs can help keep pace with industry change and support long-term growth.

Data and Integration as a Basis for Compliance and AI

The speed at which a medtech company can respond to regulatory change depends heavily on its data and integration strategy. Clear ownership of master, transactional, and reference data—covering products, suppliers, and health authority requirements—and data standards allow organizations to ensure a single source of truth powers automated reporting. Integration standards based on hub-and-spoke or publish/subscribe models help manage complexity and create consistent communication across markets and partners.

As remote monitoring, post-market surveillance, and sustainability reporting requirements expand, unified data and well-governed integrations will be essential. Fragmented systems can increase the need for data reconciliation and create friction for compliance and transparency, but a concerted effort to build harmonized data and systems can help companies remain compliant and keep products on the market.

This infrastructure will also provide an important foundation for artificial intelligence. As AI moves from pilot projects to driving core operational efficiency, its success depends on the maturity of underlying architecture. Without this foundation, AI initiatives risk being standalone plug-in tools, leading to “islands of automation” that fail to deliver enterprise-scale efficiencies.

AI relies on many of the same principles as sound architectural design. To train and run reliable models, pillar applications enable digitized processes and leverage trusted, high-quality data and robust integrations to ensure interoperability and timely refreshes. A solid enterprise architecture not only creates the groundwork for AI and automation to drive efficiency and innovation but also helps maintain security and transparency as mandated by legislation such as the EU AI Act.

Growth and M&A Rapidly Multiply Complexity

Few things accelerate complexity faster than mergers, acquisitions, or divestitures. The architectural needs of medtech companies differ greatly depending on their stage, meaning that each business in an M&A scenario arrives with its own systems, data standards, quality processes, and regulatory histories. Without a clear enterprise design, these differences remain in place, leading to parallel processes and costly transition service agreements that can linger for years.

Smaller medtechs sometimes defer system design decisions in the early years to save on time or costs, only to find later that the accumulated complexity makes growth slow and expensive. Companies that establish a clear, scalable enterprise architecture early can build a foundation for growth and integrate into new businesses faster if M&A comes into play.

Large organizations can benefit from establishing a “lighthouse” design, where a specific business unit or geography can act as a proving ground for a new application architecture before a global rollout. In a similar fashion, a simplified and standardized architecture can reduce risk and provide a “docking station” for a smooth transition during an integration or separation.

This same approach can also help companies navigate divestitures, which require extraction of a business unit’s data and systems from a highly integrated environment. To simplify carve-outs, strategic architecture with reduced customization can prevent disruption and keep separation costs low. For the seller, this reduces the long-term burden of supporting a former business unit. For the buyer, this ensures a functional data and technology background ready for integration into a new ecosystem.

For companies big and small, a well-structured architecture enables growth and protects the value of that growth from fragmentation and friction during M&A or divestitures. Companies that design their architecture for scale and flexibility can reduce transition risks and costs, while speeding execution during times of growth and change.

Mastering Registrations for Faster Speed-to-Market

One prominent hurdle for growth in medtech is product registrations. Changes to legal entities, tax strategy, or shared services can trigger re-registrations that take months or years. Since errors in executing this process can create significant compliance risk and financial exposure, companies can spend significant regulatory resources depending on the market and health authorities involved.

The stakes are particularly high. In fact, 20% of 510(k) submissions are not accepted for initial review by the FDA, and two-thirds require additional information. In the European market, approximately 25% of MDR applications are refused due to classification or completeness issues, leading to repeat reviews and delayed product launches. Since each submission can take years and cost millions, these delays have a direct impact on the bottom line.

Building a connected regulatory backbone helps companies inventory their registrations, model the impact of organizational or system changes, and streamline submissions to avoid bottlenecks. Strong registration capabilities support faster market entry, smoother integration after acquisitions, and more reliable compliance overall.

Building a Future-Ready Foundation

This year’s regulatory surge emphasizes the importance of treating architecture as a strategic discipline—linking organizational design, pillar applications, and a framework for data and integration into a single, forward-looking blueprint. This approach to holistic design can help organizations move with speed and efficiency.

Enterprise transformation in medtech is ultimately about creating profitable, compliant growth to bring products to patients faster. Companies that invest in connected, future-ready architectures will be better positioned to meet complex and overlapping requirements, enter new markets, and innovate with confidence.

MORE FROM THIS AUTHOR:

Seth Goldenberg is responsible for the strategic direction of Veeva MedTech. He works across strategy, sales, marketing, services, and product to ensure success across clinical, quality, regulatory, and commercialization in the medical device and diagnostics industry. He has over 20 years of experience helping navigate complex regulations and improve market access. He holds a doctorate in pharmacology from the University of Washington and a master’s degree in biomedical engineering from Drexel.